Acta Oncologica
Volume 59, 2020 - Issue 12
LETTERS TO THE EDITOR: MEDICAL ONCOLOGY AND HEMATHOLOGY
Combining epigenetic therapy with venetoclax overcomes alemtuzumab resistance in T-cell prolymphocytic leukemia. A case report of a 26-year-old man with a prior history of T-cell acute lymphoblastic leukemia and GI-T lymphoma
Michael Asger Andersena Department of Haematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark;b Department of Epidemiology Research, Statens Serum Institut, Copenhagen, DenmarkCorrespondence[email protected]
https://orcid.org/0000-0001-9729-9974View further author information
https://orcid.org/0000-0001-9729-9974View further author information, Rebecca Valentina Department of Haematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark;c Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USAhttps://orcid.org/0000-0001-8339-0902View further author information
https://orcid.org/0000-0001-8339-0902View further author information, , , Kjeld Schmiegelowf Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital, Copenhagen, Denmark;g Institute of Clinical Medicine, Faculty of Medicine, University of Copenhagen, Copenhagen, Denmarkhttps://orcid.org/0000-0002-0829-4993View further author information
https://orcid.org/0000-0002-0829-4993View further author information, , , & Carsten Utoft Niemanna Department of Haematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmarkhttps://orcid.org/0000-0001-9880-5242View further author information
https://orcid.org/0000-0001-9880-5242View further author information show all